Antibody Production More With Covishield Compared to Covaxin

Study by Indian doctors says that both Covaxin & Covishield are effective, but, Covishield shows ‘significantly higher’ seropositivity rate & anti-spike antibody titre.

Covishield and Covaxin produce a “good immune response” but AstraZeneca's Covishield produces “significantly higher” seropositivity rate and anti-spike antibody titre, as per the study published in Medrxiv.

The study was done on 515 healthcare workers from 13 States and covering 22 cities from January to May 2021. 95 per cent showed seropositivity after the two doses of both vaccines.

COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.

‘Covishield has a greater ability to produce more anti spike antibodies and higher seropositivity rate among Indian COVID-19 vaccines.’
Read More..

Blood samples were also tested for the presence, quantity of antibodies produced and levels of the specific antibodies that are directed to the spike protein of the virus, widely held to be a proxy of protection.

“Of the 425 Covishield and 90 Covaxin recipients, 98.1% and 80.0% respectively, showed seropositivity,” said the study, adding that the “median interquartile rise” in anti-spike antibodies was also “significantly higher in Covishield vs Covaxin recipient” at 127 AU/mL and 53.0 AU/mL respectively.

Study compared post-vaccination immune responses of participants with a history of COVID-19, and those who didn’t. It found that participants who had recovered from COVID-19 at least six weeks before the first dose, and took both shots, were 100 per cent sero positive and had higher antibody titres, too.

“Both vaccines showed good and similar immune responses even after a single dose in people who already had Covid in the past. This suggests both vaccines work well,” said Awadhesh Kumar Singh, lead author of the study and consultant endocrinologist, G.D. Hospital and Diabetes Institute, Kolkata.

“It, however, appears that Covishield may have a greater ability to produce more anti spike antibodies and higher seropositivity rate,” he added.

“We could also produce some real world evidence to show that Covaxin induces good protective antibodies after the two doses in the absence of published Phase 3 data at the moment. Covishield has already published its Phase 3 data.”

On whether the study measured vaccine efficacy beyond antibodies, the lead author told ThePrint: “While this study adds to evidence, in the absence of measuring more specific neutralizing antibody and other cell mediated immunity response — it is difficult to comment whether one is superior to other. Only randomised head to head trial can conclude anything.”

Source-Medindia